Form 5 - Annual statement of changes in beneficial ownership of securities:
SEC Accession No. 0001493152-20-002881
Filing Date
2020-02-24
Accepted
2020-02-24 14:16:10
Documents
1
Period of Report
2019-12-31

Document Format Files

Seq Description Document Type Size
1 ownership.html 5  
1 ownership.xml 5 4102
  Complete submission text file 0001493152-20-002881.txt   5722
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Issuer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 7389 Services-Business Services, NEC

Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address
Barrage Khalil (Reporting) CIK: 0001666011 (see all company filings)

Type: 5 | Act: 34 | File No.: 000-51353 | Film No.: 20643593